New drug duo takes on tough lymphoma

NCT ID NCT05685173

Recruiting now Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests an experimental drug called REGN5837 combined with the approved drug odronextamab for people with aggressive B-cell lymphoma that has come back or not responded to prior treatments. The study first finds a safe dose, then checks how well the combo works. About 107 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGN5837 (an experimental immune-boosting drug) combined with odronextamab (an approved lymphoma drug)
What this could lead to: If this works, it could offer a new treatment option for people with aggressive B-cell lymphoma that has not responded to other therapies.
What could go wrong: This is an early Phase 1 trial with only 107 participants, so it is too soon to know if the combination is safe or effective. Side effects are possible, and the drugs may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL NON-HODGKINS LYMPHOMA (B-NHL)

Contacts and locations

Locations

Amsterdam University Medical Centre, location AMC
RECRUITING

Amsterdam, 1100AZ, Netherlands
CHU de Bordeaux
RECRUITING

Talence, New Aquitaine, 33404, France
City of Hope
RECRUITING

Duarte, California, 91010, United States
Erasmus Medical Center Rotterdam
RECRUITING

Rotterdam, South Holland, 3015, Netherlands
Gustave Roussy
RECRUITING

Villejuif, Île-de-France Region, 94800, France
Harvard Medical School - Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Hopital Saint Louis
RECRUITING

Paris, 75010, France
Hospital Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
NYU Langone Health Perlmutter Cancer Center
RECRUITING

New York, New York, 10016, United States
Norton Cancer Institute
RECRUITING

Louisville, Kentucky, 40207, United States
Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital
RECRUITING

Truro, Cornwall, TR1 3LJ, United Kingdom
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States
Southampton General Hospital
RECRUITING

Southampton, Hampshire, SO16 6YD, United Kingdom
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
UT Southwestern
RECRUITING

Dallas, Texas, 75390, United States
University Hospital and Research Institute
RECRUITING

Madrid, 28041, Spain
University of California Los Angeles (UCLA) Medical Center
RECRUITING

Santa Monica, California, 90404, United States
Western General Hospital
RECRUITING

Edinburgh, Scotland, EH4 2XU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.